Amneal Pharmaceuticals Inc-A 2026年季度报告

Form 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period fromtoCommission file number 001-38485Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware93-4225266(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)Amneal Pharmaceuticals, Inc.400 Crossing Boulevard,Bridgewater, NJ08807(Address of principal executive offices)(Zip Code) (908) 947-3120(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act: Large accelerated filer Non-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of April30, 2026, there were 319,022,792 shares of the registrant’s Class A common stock outstanding, with a par value of $0.01. Amneal Pharmaceuticals, Inc. Table of Contents Cautionary Note Regarding Forward-Looking Statements PART I - FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Consolidated Statements of OperationsConsolidated Statements of Comprehensive Income (Loss)Consolidated Balance SheetsConsolidated Statements of Cash FlowsConsolidated Statements of Changes in Stockholders’ DeficiencyNotes to Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II - OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits Signatures This Quarterly Report on Form 10-Q and other publicly available documents of Amneal Pharmaceuticals, Inc. contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States (“U.S.”) Private Securities LitigationReform Act of 1995. Management and representatives of Amneal Pharmaceuticals, Inc. and its subsidiaries (“the Company”, “we”,“us”, or “our”) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly tohistorical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “targets,” “estimates,” andother words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating resultsand financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development; regulatoryapprovals; market position and expenditures. Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they aresubject to uncertainties, risks and changes that are difficult to predict and many of which are outside of our control. Investors shouldrealize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors orcircumstances change, our actual results and financial condition could vary materially from expectations and projections expressed orimplied in our forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Summary of Material Risks Risks and uncertainties that make an investment in the Compa